SAN DIEGO, Feb. 1, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage firm centered on degrading proteins to create life-saving medicines, at this time introduced the appointment of Jamie Donadio as Chief Monetary Officer. Mr. Donadio brings greater than twenty years of expertise as a monetary chief to BioTheryX, with a robust background in capital elevating, monetary technique and monetary planning.
“Jamie is a confirmed chief who has vital experience in constructing and rising an organization’s monetary infrastructure and I am thrilled to welcome him as Chief Monetary Officer,” stated Rob Williamson, President and CEO of BioTheryX. “Jamie’s latest expertise in rising Mirati, coupled together with his monitor document of profitable financings for corporations throughout key durations of development, shall be invaluable to us as we search to fund our pipeline of focused protein degraders and modulators.”
Mr. Donadio joins BioTheryX from Mirati Therapeutics, Inc., the place he served most just lately as Senior Vice President and Chief Monetary Officer and was answerable for all company finance and accounting actions since 2013. Whereas at Mirati, he performed an integral govt position throughout a interval of great development together with growth to over 100 workers and a rise in market capitalization from lower than $100 million to over $4 billion. Previous to Mirati, Mr. Donadio spent twelve years at Amylin Prescribed drugs, Inc., the place he was most just lately answerable for company finance actions together with monetary planning and evaluation, treasury and capital formation technique. Earlier than Amylin, Mr. Donadio held monetary roles at Novatel Wi-fi and Ernst & Younger.
Mr. Donadio added, “I could not think about a greater time to hitch Rob and the workforce at BioTheryX. I stay up for leveraging my expertise constructing and main company finance groups to assist BioTheryX execute on its daring technique and solidify the corporate as a pioneer in focused protein degradation.”
About BioTheryX, Inc.
BioTheryX is a clinical-stage biopharmaceutical firm centered on restoring protein homeostasis, together with protein degradation and modulation, and multi-kinase inhibition to develop therapies meant to increase and enhance the quality-of-life of sufferers with life-threatening ailments. Our principal expertise platform facilities on focused protein degradation, PHM® ‘molecular glues’, that allow the design of small molecules to manage protein equilibrium. This expertise is designed to make the most of the physique’s personal protein disposal system to selectively degrade and take away disease-causing proteins. It has potential applicability to a broad vary of ailments, together with targets that must date been thought-about ‘undruggable’. For extra data, please go to www.biotheryx.com and interact with us on LinkedIn.
SOURCE BioTheryX, Inc.